Novel insights on the role of the innate immune system in systemic sclerosis

References

• Razonable RR, Henault M, Paya CV. Stimulation of Toll-like receptor 2 with bleomycin results in cellular activation and secretion of pro-inflammatory cytokines and chemokines. Toxicol. Appl. Pharmacol.210(3), 181–189 (2006).
   PubMed Web of Science ®Google Scholar
• Baechler EC, Batliwalla FM, Karypis G et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA100(5), 2610–2615 (2003).
   PubMed Web of Science ®Google Scholar
• Bennett L, Palucka AK, Arce E et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med.197(6), 711–723 (2003).
   PubMed Web of Science ®Google Scholar
• Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity36(8), 481–490 (2003).
   PubMed Web of Science ®Google Scholar
• Kirou KA, Lee C, George S et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum.50(12), 3958–3967 (2004).
   PubMed Web of Science ®Google Scholar
• Kozyrev SV, Alarcon-Riquelme ME. The genetics and biology of Irf5-mediated signaling in lupus. Autoimmunity40(8), 591–601 (2007).
   PubMed Web of Science ®Google Scholar
• Kwok SK, Lee JY, Park SH et al. Dysfunctional interferon-alpha production by peripheral plasmacytoid dendritic cells upon Toll-like receptor-9 stimulation in patients with systemic lupus erythematosus. Arthritis Res. Ther.10(2), R29 (2008).
   Google Scholar
• Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann. Rheum. Dis.67(8), 1069–1075 (2008).
   PubMed Web of Science ®Google Scholar
• Bos CL, van Baarsen LG, Timmer TC et al. Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers. Genes Immun.10(3), 210–218 (2009).
   PubMedGoogle Scholar
• Tan FK, Zhou X, Mayes MD et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford)45(6), 694–702 (2006).
   PubMedGoogle Scholar
• York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and Toll-like receptor agonists. Arthritis Rheum.56(3), 1010–1020 (2007).
   PubMed Web of Science ®Google Scholar
• Kim D, Peck A, Santer D et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-α activity with lung fibrosis. Arthritis Rheum.58(7), 2163–2173 (2008).
   PubMedGoogle Scholar
• Barchet W, Cella M, Odermatt B, Asselin-Paturel C, Colonna M, Kalinke U. Virus-induced interferon α production by a dendritic cell subset in the absence of feedback signaling in vivo. J. Exp. Med.195(4), 507–516 (2002).
   PubMed Web of Science ®Google Scholar
• Fleming JN, Nash RA, McLeod DO et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE3(1), e1452 (2008).
   PubMed Web of Science ®Google Scholar
• Dieude P, Wipff J, Guedj M et al. BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum.60(11), 3447–3454 (2009).
   PubMedGoogle Scholar
• Dieude P, Guedj M, Wipff J et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum.60(1), 225–233 (2009).
   PubMed Web of Science ®Google Scholar
• Dieude P, Dawidowicz K, Guedj M et al. Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severity. J. Rheumatol.37(5), 987–992 (2010).
   PubMedGoogle Scholar
• Radstake TR, Gorlova O, Rueda B et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat. Genet.42(5), 426–429 (2010).
   PubMed Web of Science ®Google Scholar
• Lewis MJ, Botto M. Complement deficiencies in humans and animals: links to autoimmunity. Autoimmunity39(5), 367–378 (2006).
   PubMed Web of Science ®Google Scholar
• Ratnoff WD. Inherited deficiencies of complement in rheumatic diseases. Rheum. Dis. Clin. North Am.22(1), 75–94 (1996).
   PubMed Web of Science ®Google Scholar
• Welch TR, Blystone LW. Renal disease associated with inherited disorders of the complement system. Pediatr. Nephrol.24(8), 1439–1444 (2008).
   PubMedGoogle Scholar
• Gold LS, Ward MH, Dosemeci M, De Roos AJ. Systemic autoimmune disease mortality and occupational exposures. Arthritis Rheum.56(10), 3189–3201 (2007).
   PubMed Web of Science ®Google Scholar
• Hornung V, Bauernfeind F, Halle A et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol.9(8), 847–856 (2008).
   PubMed Web of Science ®Google Scholar
• Ahmed SS, Tan FK, Arnett FC, Jin L, Geng YJ. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum.54(7), 2250–2262 (2006).
   PubMedGoogle Scholar
• Jun JB, Kuechle M, Harlan JM, Elkon KB. Fibroblast and endothelial apoptosis in systemic sclerosis. Curr. Opin. Rheumatol.15(6), 756–760 (2003).
   PubMed Web of Science ®Google Scholar
• Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J. Clin. Invest.98(3), 785–792 (1996).
   PubMed Web of Science ®Google Scholar
• Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum.43(11), 2550–2562 (2000).
   PubMed Web of Science ®Google Scholar
• Cai P, Khan MF, Kaphalia BS, Ansari GA. Immunotoxic response of oleic acid anilide and its hydrolysis products in female MRL+/+ mice. J. Immunotoxicol.2(4), 231–236 (2005).
   PubMedGoogle Scholar
• Patterson R , Germolec D. Review article toxic oil syndrome: review of immune aspects of the disease. J. Immunotoxicol.2(1), 51–58 (2005).
   PubMedGoogle Scholar
• Cárdaba B, del Pozo V, Gallardo S, Palomino P, Posada M, Lahoz C. Genetic approaches in the understanding of toxic oil syndrome. Toxicol. Lett.161(1), 83–88 (2006).
   PubMedGoogle Scholar
• Gallardo S, Cardaba B, Posada M et al. Toxic oil syndrome: genetic restriction and immunomodulatory effects due to adulterated oils in a model of HLA transgenic mice. Toxicol. Lett.159(2), 173–181 (2005).
   PubMedGoogle Scholar
• Koller LD, Stang BV, Hall JA, Posada de la PM, Ruiz Mendez MV. Immunoglobulin and autoantibody responses in MRL/lpr mice treated with ‘toxic oils’. Toxicology178(2), 119–133 (2002).
   PubMed Web of Science ®Google Scholar
• Rao T, Richardson B. Environmentally induced autoimmune diseases: potential mechanisms. Environ. Health Perspect.107(Suppl. 5), 737–742 (1999).
   PubMed Web of Science ®Google Scholar
• Loos T, Dekeyzer L, Struyf S et al. TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis. Lab. Invest.86(9), 902–916 (2006).
   PubMedGoogle Scholar
• Ospelt C, Brentano F, Rengel Y et al. Overexpression of Toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: Toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum.58(12), 3684–3692 (2008).
   PubMed Web of Science ®Google Scholar
• Abdollahi-Roodsaz S, Joosten LA, Roelofs MF et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum.56(9), 2957–2967 (2007).
   PubMed Web of Science ®Google Scholar
• Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum.52(9), 2656–2665 (2005).
   PubMed Web of Science ®Google Scholar
• Farina G, York M, Collins C, Lafyatis R. dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts. Ann. Rheum. Dis.70(3), 544–550 (2011).
   PubMedGoogle Scholar
• Farina GA, York MR, Di MM et al. Poly(I:C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J. Invest. Dermatol.130(11), 2583–2593 (2010).
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Wu M, Livingston CK et al. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res. Ther.13(1), R3 (2011).
   PubMed Web of Science ®Google Scholar
• Kleinman ME, Yamada K, Takeda A et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature452(7187), 591–597 (2008).
   PubMed Web of Science ®Google Scholar
• Choi J, Walker J, Boichuk S et al. Human endothelial cells enhance human immunodeficiency virus type 1 replication in CD4+ T cells in a Nef-dependent manner in vitro and in vivo. J. Virol.79(1), 264–276 (2005).
   PubMedGoogle Scholar
• Robitaille G, Henault J, Christin MS, Senecal JL, Raymond Y. The nuclear autoantigen CENP-B displays cytokine-like activities toward vascular smooth muscle cells. Arthritis Rheum.56(11), 3814–3826 (2007).
   PubMedGoogle Scholar
• Henault J, Tremblay M, Clement I, Raymond Y, Senecal JL. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum.50(10), 3265–3274 (2004).
   PubMedGoogle Scholar
• Henault J, Robitaille G, Senecal JL, Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum.54(3), 963–973 (2006).
   PubMed Web of Science ®Google Scholar
• Montgomery H, O’Leary PA, Ragsdale WE Jr. Dermatohistopathology of various types of scleroderma. AMA. Arch. Derm.75(1), 78–87 (1957).
   PubMedGoogle Scholar
• Marshall JS, McCurdy JD, Olynych T. Toll-like receptor-mediated activation of mast cells: implications for allergic disease? Int. Arch. Allergy Immunol.132(2), 87–97 (2003).
   PubMed Web of Science ®Google Scholar
• Matsushima H, Yamada N, Matsue H, Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J. Immunol.173(1), 531–541 (2004).
   PubMed Web of Science ®Google Scholar
• Mrabet-Dahbi S, Metz M, Dudeck A, Zuberbier T, Maurer M. Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. Exp. Dermatol.18(5), 437–444 (2009).
   PubMed Web of Science ®Google Scholar
• Clements PJ, Furst DE. Systemic Sclerosis. Lipincott Williams & Wilkins, PA, USA (2004).
   Google Scholar
• Gruber BL. Mast cells in the pathogenesis of fibrosis. Curr. Rheumatol. Rep.5(2), 147–153 (2003).
   PubMedGoogle Scholar
• Hugle T, Hogan V, White KE, van Laar JM. Mast cells are a source of transforming growth factor-β in systemic sclerosis. Arthritis & Rheumatism63(3), 795–799 (2011).
   PubMedGoogle Scholar
• Gelbmann CM, Mestermann S, Gross V, Kollinger M, Scholmerich J, Falk W. Strictures in Crohn’s disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut45(2), 210–217 (1999).
   PubMed Web of Science ®Google Scholar
• Atkins SR, Matteson EL, Myers JL, Ryu JH, Bongartz T. Morphological and quantitative assessment of mast cells in rheumatoid arthritis associated non-specific interstitial pneumonia and usual interstitial pneumonia. Ann. Rheum. Dis.65(5), 677–680 (2006).
   PubMedGoogle Scholar
• Akgul A. Can cardiac fibrosis be prevented? Mast cell inhibition versus anti-chymase activity. Eur. J. Cardiothorac. Surg.35(3), 553–554 (2009).
   PubMedGoogle Scholar
• Seibold JR, Giorno RC, Claman HN. Dermal mast cell degranulation in systemic sclerosis. Arthritis Rheum.33(11), 1702–1709 (1990).
   PubMedGoogle Scholar
• Yamamoto T, Takahashi Y, Takagawa S, Katayama I, Nishioka K. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice. J. Rheumatol.26(12), 2628–2634 (1999).
   PubMed Web of Science ®Google Scholar
• Mori H, Kawada K, Zhang P, Uesugi Y, Sakamoto O, Koda A. Bleomycin-induced pulmonary fibrosis in genetically mast cell-deficient WBB6F1-W/Wv mice and mechanism of the suppressive effect of tranilast, an antiallergic drug inhibiting mediator release from mast cells, on fibrosis. Int. Arch. Allergy Appl. Immunol.95(2–3), 195–201 (1991).
   PubMedGoogle Scholar
• Tomimori Y, Muto T, Saito K et al. Involvement of mast cell chymase in bleomycin-induced pulmonary fibrosis in mice. Eur. J. Pharmacol.478(2–3), 179–185 (2003).
   PubMedGoogle Scholar
• Marshall JS, Leal-Berumen I, Nielsen L, Glibetic M, Jordana M. Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J. Clin. Invest.97(4), 1122–1128 (1996).
   PubMed Web of Science ®Google Scholar
• Marshall JS, McCurdy JD, Olynych T. Toll-like receptor-mediated activation of mast cells: implications for allergic disease? Int. Arch. Allergy Immunol.132(2), 87–97 (2003).
   PubMed Web of Science ®Google Scholar
• McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J. Immunol.170(4), 1625–1629 (2003).
   PubMed Web of Science ®Google Scholar
• Supajatura V, Ushio H, Nakao A et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J. Clin. Invest.109(10), 1351–1359 (2002).
   PubMed Web of Science ®Google Scholar
• Fisher ER, Rodnan GP. Pathologic observations concerning the cutaneous lesion of progressive systemic sclerosis: an electron microscopic histochemical and immunohistochemical study. Arthritis Rheum.3, 536–545 (1960).
   PubMedGoogle Scholar
• Biesen R, Demir C, Barkhudarova F et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum.58(4), 1136–1145 (2008).
   PubMedGoogle Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol.22(11), 633–640 (2001).
   PubMed Web of Science ®Google Scholar
• Deniz G, Erten G, Kucuksezer UC et al. Regulatory NK cells suppress antigen-specific T cell responses. J. Immunol.180(2), 850–857 (2008).
   PubMed Web of Science ®Google Scholar
• Horikawa M, Hasegawa M, Komura K et al. Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity. J. Invest. Dermatol.125(4), 731–737 (2005).
   PubMed Web of Science ®Google Scholar
• Grazia CM, Giacomelli R, Famularo G et al. Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis. Clin. Exp. Immunol.80(3), 360–365 (1990).
   PubMedGoogle Scholar
• Kantor TV, Whiteside TL, Friberg D, Buckingham RB, Medsger TA Jr. Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis. Arthritis Rheum.35(6), 694–699 (1992).
   PubMedGoogle Scholar
• Wanchu A, Singh VK, Yadav VS, Biswas S, Misra R, Agarwal SS. Lack of natural killer cell augmentation in vitro by human interferon gamma in a subset of patients with systemic sclerosis. Pathobiology63(5), 288–292 (1995).
   PubMedGoogle Scholar
• Wright JK, Hughes P, Rowell NR. Spontaneous lymphocyte-mediated (NK cell) cytotoxicity in systemic sclerosis: a comparison with antibody-dependent lymphocyte (K cell) cytotoxicity. Ann. Rheum. Dis.41(4), 409–413 (1982).
   PubMed Web of Science ®Google Scholar
• Jin O, Kavikondala S, Sun L et al. Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient CD83 expression. Lupus17(7), 654–662 (2008).
   PubMedGoogle Scholar
• Krug A. Nucleic acid recognition receptors in autoimmunity. Handb. Exp. Pharmacol.183, 129–151 (2008).
   Google Scholar
• Marshak-Rothstein A, Busconi L, Rifkin IR, Viglianti GA. The stimulation of Toll-like receptors by nuclear antigens: a link between apoptosis and autoimmunity. Rheum. Dis. Clin. North Am.30(3), 559–574, ix (2004).
   PubMedGoogle Scholar
• Marshak-Rothstein A, Rifkin IR. Immunologically active autoantigens: the role of Toll-like receptors in the development of chronic inflammatory disease. Annu. Rev. Immunol.25, 419–441 (2007).
   PubMed Web of Science ®Google Scholar
• Monrad S, Kaplan MJ. Dendritic cells and the immunopathogenesis of systemic lupus erythematosus. Immunol. Res.37(2), 135–145 (2007).
   PubMed Web of Science ®Google Scholar
• Pisetsky DS. The role of innate immunity in the induction of autoimmunity. Autoimmun. Rev.8(1), 69–72 (2008).
   PubMed Web of Science ®Google Scholar
• Ronnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus17(5), 394–399 (2008).
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock L, Ancuta P, Crowe S et al. Nomenclature of monocytes and dendritic cells in blood. Blood116(16), e74–e80 (2010).
   PubMed Web of Science ®Google Scholar
• Andrews BS, Friou GJ, Barr RJ et al. Loss of epidermal Langerhans’ cells and endothelial cell HLA-DR antigens in the skin in progressive systemic sclerosis. J. Rheumatol.13(2), 341–348 (1986).
   PubMedGoogle Scholar
• Goobar JP, Fang M, Weisman MH, Zvaifler N, Gigli I. Langerhans cells in connective tissue diseases. Scand. J. Rheumatol.16(4), 273–279 (1987).
   PubMed Web of Science ®Google Scholar
• Bobr A, Olvera-Gomez I, Igyarto BZ, Haley KM, Hogquist KA, Kaplan DH. Acute ablation of Langerhans cells enhances skin immune responses. J. Immunol.185(8), 4724–4728 (2010).
   PubMedGoogle Scholar
• Guilliams M, Henri S, Tamoutounour S et al. From skin dendritic cells to a simplified classification of human and mouse dendritic cell subsets. Eur. J. Immunol.40(8), 2089–2094 (2010).
   PubMed Web of Science ®Google Scholar
• Kautz-Neu K, Noordegraaf M, Dinges S et al. Langerhans cells are negative regulators of the anti-Leishmania response. J. Exp. Med.208(5), 885–891 (2011).
   PubMed Web of Science ®Google Scholar
• van Lieshout AW, Vonk MC, Bredie SJ et al. Enhanced interleukin-10 production by dendritic cells upon stimulation with Toll-like receptor 4 agonists in systemic sclerosis that is possibly implicated in CCL18 secretion. Scand. J. Rheumatol.38(4), 282–290 (2009).
   PubMed Web of Science ®Google Scholar